In the study cohort, including 166 study HCC patients with CPR and 184 control patients with PPR, the PPR group showed a median AFP of 12.4 ng/mL (25–75 percentiles: 5.0–56.3) (p < 0.001 compared with CPR) and a median PIVKA-II of 23 (25–75 percentiles: 15–53) (p < 0.001 compared with CPR; Figure 3). Here, AFP is linked to hepatocellular carcinoma.